Press Releases
- Dec 17, 2024Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025Read More
- Dec 10, 2024NORDICUS now trading under symbol NORDRead More
- Nov 12, 2024Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/SRead More
- Nov 11, 2024Nordicus Partners Corporation Acquires Bio-Convert ApSRead More
- Nov 7, 2024Nordicus Partners Corporation Announces Reverse Stock SplitRead More
- Jul 3, 2024Nordicus Partners To Host Investor Relations Webinar on July 10, 2024Read More
- Jun 21, 2024Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In DenmarkRead More
- Jun 11, 2024Orocidin – New Insights Into The Treatment Of PeriodontitisRead More
- Jun 4, 2024Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of DirectorsRead More
- May 23, 2024Nordicus Partners Corporation Engages FORCE Family OfficeRead More
- May 15, 2024Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/SRead More
- May 9, 2024Nordicus Partners Corporation Uplists to OTCQBRead More
- Jan 10, 2024Nordicus Partners Corporation Enters Into a Consultancy Agreement with Orocidin A/S in DenmarkRead More